Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer

被引:32
|
作者
Takamori, Shinkichi [1 ]
Toyokawa, Gouji [1 ]
Okamoto, Isamu [2 ]
Takada, Kazuki [1 ,3 ]
Kozuma, Yuka [1 ]
Matsubara, Taichi [1 ]
Haratake, Naoki [1 ]
Akamine, Takaki [1 ]
Katsura, Masakazu [1 ]
Mukae, Nobutaka [4 ]
Shoji, Fumihiro [1 ]
Okamoto, Tatsuro [1 ]
Oda, Yoshinao [3 ]
Iwaki, Toru [5 ]
Iihara, Koji [4 ]
Nakanishi, Yoichi [2 ]
Maehara, Yoshihiko [1 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 8128582, Japan
[2] Kyushu Univ, Chest Grad Sch Med Sci, Res Inst Dis, Fukuoka, Japan
[3] Kyushu Univ, Dept Anat Pathol, Grad Sch Med Sci, Fukuoka, Japan
[4] Kyushu Univ, Dept Neurosurg, Grad Sch Med Sci, Fukuoka, Japan
[5] Kyushu Univ, Dept Neuropathol, Neurol Inst, Grad Sch Med Sci, Fukuoka, Japan
关键词
Programmed cell death-ligand 1; immunotherapy; non-small cell lung cancer; BRAIN METASTASES; PREDICTIVE BIOMARKERS; EXPRESSION; PD-L1; PEMBROLIZUMAB; ALECTINIB; NIVOLUMAB; ERLOTINIB; CHEMOTHERAPY; CRIZOTINIB;
D O I
10.21873/anticanres.11813
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To investigate the discordance in the programmed cell death-ligand 1 (PD-L1) expression between primary and metastatic tumors and analyze the association between the discordance and the clinical factors in non-small cell lung cancer (NSCLC) patients. Patients and Methods: Twenty-one NSCLC patients who underwent surgery or biopsy for paired primary and metastatic lesions at our Institution from 2005 to 2016 were analyzed. Lesions with the PD-L1 expression being >= 5% were considered PD-L1-positive. Results: The metastatic sites included the brain (n=16), adrenal gland (n=3), spleen (n=1) and jejunum (n=1). Negative conversion of the primary PD-L1-positive NSCLC and positive conversion of the primary PD-L1-negative NSCLC were observed in 3 (14%) and 2 (10%) cases, respectively. Radiotherapy for the metastatic brain lesion before its resection showed a significant relationship with the positive conversion of the primary PD-L1-negative NSCLC (p=0.048). Conclusion: Radiotherapy-derived effects may contribute to the positive conversion of the primary PD-L1-negative NSCLC.
引用
收藏
页码:4223 / 4228
页数:6
相关论文
共 50 条
  • [11] Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?
    Gainor, Justin F.
    CANCER CYTOPATHOLOGY, 2017, 125 (08) : 591 - 593
  • [12] Heterogeneity and prognosis of programmed cell death-ligand 1 expression in the circulating tumor cells of non-small cell lung cancer
    Wang, He-Lin
    Wu, Jie-Qing
    Wang, Ying
    Yu, Jian
    Mao, Xiao-Na
    Li, Zhuo-Ran
    Niu, Hong-Rui
    Jin, Cai-Ling
    Wang, Xiao-Jue
    Yan, Zhuo-Hong
    Yi, Ling
    Yang, Bin
    Wei, Pan-Jian
    Zhang, Hong-Tao
    Zhang, Shu-Cai
    NEOPLASMA, 2021, 68 (04) : 823 - 831
  • [13] Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer
    Yu, Hui
    Brustugun, Odd Terje
    Ekman, Simon
    Botling, Johan
    La Fleur, Linnea
    Micke, Patrick
    Solberg, Steinar
    Berglund, Anders
    Rivard, Christopher
    Hirsch, Fred R.
    CLINICAL LUNG CANCER, 2021, 22 (04) : E555 - E562
  • [14] Avelumab-a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer
    Gil-Bazo, Ignacio
    TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 : S35 - S38
  • [15] Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature review
    Bai, Yibing
    Yang, Wenyu
    Kasmann, Lukas
    Sorich, Michael J.
    Tao, Haitao
    Hu, Yi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (02) : 398 - 422
  • [16] Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer
    Chen, Jingyi
    Chen, Yusong
    Feng, Fenglan
    Chen, Cheng
    Zeng, Haikang
    Wen, Shuai
    Xu, Xin
    He, Jianxing
    Li, Jin
    JOURNAL OF THORACIC DISEASE, 2018, 10 (12) : 6711 - +
  • [17] Programmed death ligand-1 expression in non-small cell lung cancer
    Velcheti, Vamsidhar
    Schalper, Kurt A.
    Carvajal, Daniel E.
    Anagnostou, Valsamo K.
    Syrigos, Konstantinos N.
    Sznol, Mario
    Herbst, Roy S.
    Gettinger, Scott N.
    Chen, Lieping
    Rimm, David L.
    LABORATORY INVESTIGATION, 2014, 94 (01) : 107 - 116
  • [18] Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer
    Kim, Hyojin
    Kwon, Hyun Jung
    Park, Soo Young
    Park, Youngmi
    Park, Eunhyang
    Chung, Jin-Haeng
    PLOS ONE, 2018, 13 (06):
  • [19] Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer
    Villaruz, Liza C.
    Blumenschein Jr, George R.
    Otterson, Gregory A.
    Leal, Ticiana A.
    CANCER, 2023, 129 (09) : 1319 - 1350
  • [20] Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?
    Acheampong, Emmanuel
    Spencer, Isaac
    Lin, Weitao
    Ziman, Melanie
    Millward, Michael
    Gray, Elin
    CANCERS, 2019, 11 (07)